Definium Therapeutics Q1 net loss widens on higher R&D costs

Definium Therapeutics

07/05/2026 21:11

Overview

US biopharma firm posted wider Q1 net loss as R&D and admin expenses increased

Company ended Q1 with $373.4 mln in cash, seen funding operations into 2028

Definium completed enrollment in key Phase 3 trials and plans PTSD study in 2027

Outlook

Definium expects topline data from three Phase 3 DT120 ODT studies by end of 3Q 2026

Company plans to initiate Phase 3 Haven study in PTSD in 2027

Definium expects current cash and investments to fund operations into 2028

Result Drivers

DT120 ODT TRIAL EXPENSES - Co said higher R&D costs were mainly due to increased spending on DT120 ODT clinical trials

ADMIN COSTS - Co attributed higher G&A expenses to stock-based compensation, personnel, commercial preparedness, and legal expenses

PIPELINE EXPANSION - Co expanded DT120 ODT program into PTSD, with new Phase 3 study planned for 2027

Company press release: ID:nBw8nj3bMa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.71
Q1 Net Income
-$77.10 mln
Q1 Basic EPS
-$0.71
Q1 Income from Operations
-$59.22 mln
Q1 Operating Expenses
$59.22 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Definium Therapeutics Inc is $38.00, about 62.3% above its May 6 closing price of $23.42

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)